Evidências clínicas do uso da azitromicina durante a pandemia de Sars-Cov-2 (COVID-19) – uma revisão bibliográfica
Arquivos
Data
2023-06-13
Autores
Santos, Juliano Maia dos 
Orientadores
Garcia, Raphael Caio Tamborelli
Tipo
Trabalho de conclusão de curso
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Em meio à busca de formas de tratamento eficazes contra a COVID-19, alguns protocolos de tratamento foram estudados no período. Determinadas classes de medicamentos fizeram parte desses estudos, como os antimicrobianos, especialmente a azitromicina, fármaco em potencial devido às evidências promissoras em testes in vitro. Por esta razão, a azitromicina foi escolhida como objeto de estudo do presente trabalho, cujo objetivo principal foi investigar os aspectos clínicos da utilização deste fármaco no tratamento da COVID-19. A plataforma PubMed foi utilizada como ferramenta de busca dos artigos utilizados neste trabalho. Os termos de busca utilizados foram “azitromicina, COVID-19, coronavírus e antibioticoterapia”. Foram pré-selecionados 1.412 artigos a partir de 2020 que passaram por uma triagem de título e resumo. Os critérios de exclusão foram artigos que não eram estudos clínicos, ano de publicação anterior à 2020 e estudos envolvendo associações da azitromicina com os fármacos cloroquina e hidroxicloroquina. No total, quatro artigos atenderam aos requisitos estabelecidos e foram utilizados para a elaboração do trabalho. Foi identificada a ausência de benefícios consideráveis em todos os artigos estudados, mostrando a falta de efetividade da azitromicina no tratamento dos sintomas da COVID-19, com exceção à possíveis casos de infecções secundárias. Apesar disso, pode-se constatar um crescimento do seu consumo em meio a pandemia. Portanto, apesar de novos estudos sempre serem necessários, pode-se concluir que o antimicrobiano não deve ser usado em protocolos de tratamento da COVID-19 devido à baixa eficácia.
During the search for effective forms of treatment against COVID-19, some treatment protocols were studied in the period. Certain classes of drugs were studied, such as antimicrobials, especially azithromycin which presented a potential in vitro activity. For this reason, azithromycin was chosen as the object of study of the present work, which aimed to investigate the clinical aspects of this drug for the treatment of COVID-19. The PubMed platform was used as a search tool for the articles used in this work. The search terms used were azithromycin, COVID-19, coronavirus and antibiotic therapy. A total of 1,412 articles from 2020 that underwent screening for title and abstract were pre-selected. Exclusion criteria were articles that were not clinical studies, year of publication prior to 2020 and studies involving associations of azithromycin with chloroquine and hydroxychloroquine drugs. Four articles met the inclusion criteria and were used in this the work. The absence of considerable benefits was identified in all articles studied, showing the lack of effectiveness of azithromycin in the treatment of COVID-19 symptoms, apart from possible cases of secondary infections. Despite of that, an increase in azithromycin was observed during the pandemics. Therefore, new studies are always needed, it can be concluded that the antimicrobial should not be used for the treatment of COVID-19 due to low efficacy.
During the search for effective forms of treatment against COVID-19, some treatment protocols were studied in the period. Certain classes of drugs were studied, such as antimicrobials, especially azithromycin which presented a potential in vitro activity. For this reason, azithromycin was chosen as the object of study of the present work, which aimed to investigate the clinical aspects of this drug for the treatment of COVID-19. The PubMed platform was used as a search tool for the articles used in this work. The search terms used were azithromycin, COVID-19, coronavirus and antibiotic therapy. A total of 1,412 articles from 2020 that underwent screening for title and abstract were pre-selected. Exclusion criteria were articles that were not clinical studies, year of publication prior to 2020 and studies involving associations of azithromycin with chloroquine and hydroxychloroquine drugs. Four articles met the inclusion criteria and were used in this the work. The absence of considerable benefits was identified in all articles studied, showing the lack of effectiveness of azithromycin in the treatment of COVID-19 symptoms, apart from possible cases of secondary infections. Despite of that, an increase in azithromycin was observed during the pandemics. Therefore, new studies are always needed, it can be concluded that the antimicrobial should not be used for the treatment of COVID-19 due to low efficacy.